In vivo antibody testing is required to evaluate the therapeutic potential of monoclonal antibodies (mAbs) and other biologics. Unlike in vitro models, which primarily offer insights into molecular interactions, in vivo studies provide essential data on an antibody's pharmacodynamics, pharmacokinetics, and overall safety profile within the complexity of living organisms.
The preclinical testing phase helps answer essential questions about an antibody's mechanism of action, including its ability to engage the immune system effectively or neutralize specific targets under physiological conditions.
These studies also assess safety and tolerability by identifying potential off-target effects, immunogenicity, and toxicity risks. Early detection of these issues ensures that only the most promising candidates proceed to clinical evaluation, reducing costly late-stage failures.
Related: Research-Use-Only (RUO) Biologics for Antibody In Vivo Research
Tools and Models for In Vivo Testing
Choosing the right in vivo model is fundamental to obtaining relevant and translatable results. Common models include rodent systems, such as mouse or rat models, which are well-suited for studying humanized antibodies and immune responses. Transgenic and knockout models further enhance the ability to study specific targets and pathways relevant to human diseases.
Regulatory Expectations
Regulatory agencies, such as the FDA and EMA, require rigorous preclinical testing to ensure the safety of antibodies before human trials. The data generated must demonstrate not only efficacy but also acceptable safety margins, including detailed toxicology reports and immune response profiles.
Adherence to Good Laboratory Practice (GLP) guidelines is essential for ensuring reproducibility and compliance. Regulatory submissions rely heavily on robust, validated in vivo data to support Investigational New Drug (IND) applications.
Biointron’s catalog products for in vivo research can be found at Abinvivo, where we have a wide range of Benchmark Positive Antibodies, Isotype Negative Antibodies, Anti-Mouse Antibodies, Bispecific Antibodies, and Antibody-Drug Conjugates. Contact us to find out more at info@biointron.com or +86 400-828-8830 / +1(732)790-8340.
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
